PPARγ and Apoptosis in Cancer

被引:111
作者
Elrod, Heath A. [1 ]
Sun, Shi-Yong [1 ]
机构
[1] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
关键词
D O I
10.1155/2008/704165
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Peroxisome proliferator-activated receptors (PPARs) are ligand binding transcription factors which function in many physiological roles including lipid metabolism, cell growth, differentiation, and apoptosis. PPARs and their ligands have been shown to play a role in cancer. In particular, PPAR gamma ligands including endogenous prostaglandins and the synthetic thiazolidinediones (TZDs) can induce apoptosis of cancer cells with antitumor activity. Thus, PPAR gamma ligands have a potential in both chemoprevention and therapy of several types of cancer either as single agents or in combination with other antitumor agents. Accordingly, the involvement of PPAR gamma and its ligands in regulation of apoptosis of cancer cells have been extensively studied. Depending on cell types or ligands, induction of apoptosis in cancer cells by PPAR gamma ligands can be either PPAR gamma-dependent or -independent. Through increasing our understanding of the mechanisms of PPAR gamma ligand-induced apoptosis, we can develop better strategies which may include combining other antitumor agents for PPAR gamma-targeted cancer chemoprevention and therapy. This review will highlight recent research advances on PPAR gamma and apoptosis in cancer. Copyright (C) 2008 H. A. Elrod and S.-Y. Sun.
引用
收藏
页数:12
相关论文
共 81 条
[1]   A peroxisome proliferator-activated receptor-γ agonist, troglitazone, facilitates caspase-8 and-9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells [J].
Akasaki, Y ;
Liu, GT ;
Matundan, HH ;
Ng, HS ;
Yuan, XP ;
Zeng, ZH ;
Black, KL ;
Yu, JS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (10) :6165-6174
[2]   Death receptors: Signaling and modulation [J].
Ashkenazi, A ;
Dixit, VM .
SCIENCE, 1998, 281 (5381) :1305-1308
[3]   Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions [J].
Avis, I ;
Hong, SH ;
Martínez, A ;
Moody, T ;
Choi, YH ;
Trepel, J ;
Das, R ;
Jett, M ;
Mulshine, JL .
FASEB JOURNAL, 2001, 15 (09) :2007-+
[4]   Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition [J].
Avis, I ;
Martínez, A ;
Tauler, J ;
Zudaire, E ;
Mayburd, A ;
Abu-Ghazaleh, R ;
Ondrey, F ;
Mulshine, JL .
CANCER RESEARCH, 2005, 65 (10) :4181-4190
[5]   Expression of NAG-1, a transforming growth factor-β superfamily member, by troglitazone requires the early growth response gene EGR-1 [J].
Baek, SJ ;
Kim, JS ;
Nixon, JB ;
DiAugustine, RP ;
Eling, TE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (08) :6883-6892
[6]   Troglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) ligand, selectively induces the early growth response-1 gene independently of PPARγ -: A novel mechanism for its anti-tumorigenic activity [J].
Baek, SJ ;
Wilson, LC ;
Hsi, LC ;
Eling, TE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (08) :5845-5853
[7]   Peroxisome proliferator-activated receptor-γ activates p53 gene promoter binding to the nuclear factor-κB sequence in human MCF7 breast cancer cells [J].
Bonofiglio, Daniela ;
Aquila, Saveria ;
Catalano, Stefania ;
Gabriele, Sabrina ;
Belmonte, Maria ;
Middea, Emilia ;
Qi, Hongyan ;
Morelli, Catia ;
Gentile, Mariaelena ;
Maggiolini, Marcello ;
Ando, Sebastiano .
MOLECULAR ENDOCRINOLOGY, 2006, 20 (12) :3083-3092
[8]   Peroxisome proliferator-activated receptor-γ antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines [J].
Burton, Jack D. ;
Castillo, Mary E. ;
Goldenberg, David M. ;
Blumenthal, Rosalyn D. .
ANTI-CANCER DRUGS, 2007, 18 (05) :525-534
[9]   PPARγ-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma [J].
Chaffer, CL ;
Thomas, DM ;
Thompson, EW ;
Williams, ED .
BMC CANCER, 2006, 6 (1)
[10]  
Chung Yong Woo, 2003, Korean J Gastroenterol, V42, P35